Latest Dilution News

Lefroy Exploration has partnered with BML Ventures under a profit-sharing agreement to develop the Lucky Strike gold deposit, aiming to start mining operations in the second half of 2025. This collaboration leverages BML's mining expertise and funding, while Lefroy retains half the profits from the project.

Commonwealth Bank of Australia announces a fully franked ordinary dividend of AUD 2.25 per share, payable March 28, 2025, reflecting solid financial results for the period ending December 31, 2024.

Argenica Therapeutics reported a 16% reduction in half-year losses to $1.19 million, buoyed by a 29% increase in other income largely from R&D tax incentives, as it advances its neuroprotective drug development.

BKI Investment Company Limited has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.039 per share and providing key details on its Dividend Reinvestment Plan (DRP).

Elixir Energy Limited has had its ASX trading suspension lifted following a pivotal announcement about expanding its Taroom Trough assets and initiating a capital raise.

Elixir Energy has expanded its footprint in Queensland's Taroom Trough through a farmin deal with Santos, boosting its contingent gas resources by 68% and launching a $9 million equity raise to fund upcoming exploration activities.

Ryder Capital Limited has announced a fully franked ordinary dividend of AUD 0.045 per share for the half-year ending December 2024, reflecting steady returns to shareholders.

Challenger Gold has reached a key milestone in its Hualilan project, finalising mine designs and schedules that increase mineral grades by 10%, while progressing toll milling readiness and operational flexibility.

Burgundy Diamond Mines showcased its vertically integrated diamond business and Ekati mine acquisition at the Bell Potter Unearthed Natural Resources Conference, outlining a robust 2025 operational and financial outlook despite market headwinds.

Wellnex Life Limited has announced a non-renounceable entitlement offer to raise approximately $22.1 million at $0.65 per share, supporting its planned AIM listing and strategic growth initiatives.

Micro-X Limited's trading suspension has been lifted following its announcement of an equity raising, signaling renewed market activity for the medical technology firm.

Micro-X has raised $3.3 million through a placement and institutional entitlement offer, reinforcing its strategic shift towards medical imaging technologies. A retail entitlement offer aiming to raise an additional $2.7 million will open shortly, supporting the company’s development of mobile X-ray and CT products.